Baker Bros. Advisors LP Apellis Pharmaceuticals, Inc. Transaction History

Baker Bros. Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $71.3 Million - $159 Million	-2,271,917 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $24.5 Million - $38.8 Million	597,913 Added 35.72%	2,271,917 $144 Million
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $31.7 Million - $44.6 Million	777,453 Added 86.72%	1,674,004 $71.8 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $7.16 Million - $17.7 Million	399,582 Added 80.4%	896,551 $24 Million
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $4.05 Million - $5.64 Million	183,244 Added 58.41%	496,969 $15.2 Million

Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $1.51 Million - $2.33 Million	117,647 Added 60.0%	313,725 $6.12 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $3.85 Million - $5.88 Million	196,078 New	196,078 $4.31 Million

337

111M

1.26M

1.14M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $4.21B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.